A Review on The Development, Production Strategies, and Utilization of Monoclonal Antibodies
Over the last 20 years, monoclonal antibodies have become the backbone of biological therapeutics for the treatment and diagnosis of several
diseases. The rising incidence of cancer and other immunologic diseases promoted the increasing investments of the global pharmaceutical
industry in monoclonal antibody development. The R&D has focused on the highest efficacy which is majorly correlated with the antigenbinding
specificity and the lowest immunogenicity of monoclonal antibodies. This review aims to provide a brief description and explanation
of each stage in the development path of mAbs.
Keywords: monoclonal antibodies, industry, cancer
___
- 1. Liu JKH. The history of monoclonal antibody development-Progress,
remaining challenges and future innovations. Ann Med Surg
2014;3:113–116. [CrossRef]
- 2. Payne WJ, Marshall DL, Shockley RK, Martin WJ. Clinical laboratory
applications of monoclonal antibodies. Clin Microbiol Rev
1988;1:313–329. [CrossRef
- 3. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody
market. mAbs 2015;7:9–14. [CrossRef]
- 4. Walker N. Innovation at the Heart of Biopharmaceutical
Industry Growth. Am Pharma Rev 2016. https://www.
americanpharmaceuticalreview.com/Featured-Articles/187354-
Innovation-at-the-Heart-of-Biopharmaceutical-Industry-Growth/
- 5. Leavy O. The birth of monoclonal antibodies. Nat Immunol
2016;17:S13. [CrossRef]
- 6. Levine HL, Cooney BR. The Development of Therapeutic Monoclonal
Antibody Products. Needham, MA: Insight Pharma Reports; 2018.
p.1–10.
- 7. Vigeral P, Chkoff N, Chatenoud L, et al. Prophylactic use of OKT3
monoclonal antibody in cadaver kidney recipients. Utilization
of OKT3 as the sole immunosuppressive agent. Transplantation
1986;41:730–733. [CrossRef]
- 8. Nicholson LB. The immune system. Essays Biochem 2016;60:275–
301. [CrossRef]
- 9. Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody Structure
and Function: The Basis for Engineering Therapeutics. Antibodies
2019;8:55. [CrossRef]
- 10. Wang Q, Chen Y, Park J, et al. Design and Production of Bispecific
Antibodies. Antibodies 2019;8:43. [CrossRef]
- 11. Tomita M, Tsumoto K. Hybridoma technologies for antibody
production. Immunotherapy 2011;3:371–380. [CrossRef]
- 12. Baron D, Peters JH, Gieseler RKH, et al. Production of Hybridomas.
In: Peters JH, Baumgarten H, editors. Monoclonal Antibodies. 1992.
p.137–222.
- 13. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic
antibodies: successes, limitations and hopes for the future. Br J
Pharmacol 2009;157:220–233. [CrossRef]
- 14. Lu RM, Hwang YC., Liu IJ, et al. Development of therapeutic antibodies
for the treatment of diseases. J Biomed Sci 2020;27:1. [CrossRef]
- 15. Yamashita M, Katakura Y, Shirahata S. Recent advances in the
generation of human monoclonal antibody. Cytotechnology
2007;55:55–60. [CrossRef]
- 16. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity
of humanized and fully human antibodies: residual immunogenicity
resides in the CDR regions. mAbs 2010;2:256–265. [CrossRef]
- 17. Tsurushita N, Hinton PR, Kumar S. Design of humanized antibodies:
from anti-Tac to Zenapax. Methods 2005;36:69–83. [CrossRef]
- 18. Williams DG, Matthews DJ, Jones T. Humanising Antibodies by CDR
Grafting. In: Kontermann R, Dübel S, editors. Antibody Engineering.
Springer Protocols Handbooks; 2010. [CrossRef]
- 19. Studnicka GM, Soares S, Better M, Williams RE, Nadell R, Horwitz
AH. Human-engineered monoclonal antibodies retain full specific
binding activity by preserving non-CDR complementaritymodulating
residues. Protein Eng 1994;7:805–814. [CrossRef]
- 20. Safdari Y, Farajnia S, Asgharzadeh M, Khalili M. Antibody
humanization methods - a review and update. Biotechnol Genet Eng
Rev 2013;29:175–186. [CrossRef]
- 21. Hwang WY, Almagro JC, Buss TN, Tan P, Foote J. Use of human
germline genes in a CDR homology-based approach to antibody
humanization. Methods 2005;36:35–42. [CrossRef]
- 22. Roguska MA, Pedersen JT, Keddy CA, et al. Humanization of murine
monoclonal antibodies through variable domain resurfacing. Proc
Nat Acad Sci U S A 1994;91:969–973. [CrossRef]
- 23. Lazar GA, Desjarlais JR, Jacinto J, Karki S, Hammond PW. A molecular
immunology approach to antibody humanization and functional
optimization. Mol Immunol 2007;44:1986–1998. [CrossRef]
- 24. Ahmadzadeh V, Farajnia S, Feizi MAH, Nejad MAK. Antibody
Humanization Methods for Development of Therapeutic
Applications. Monoclon Antib Immunodiagn Immunother
2014;33:67–73. [CrossRef]
- 25. Lonberg N, Taylor LD, Harding FA, et al. Antigen-specific human
antibodies from mice comprising four distinct genetic modifications.
Nature 1994;368:856–859. [CrossRef]
- 26. Mendez MJ, Green LL, Corvalan JR, et al. Functional transplant
of megabase human immunoglobulin loci recapitulates human
antibody response in mice. Nat Genet 1997;15:146–156. [CrossRef]
- 27. Green LL, Hardy MC, Maynard-Currie CE, et al. Antigen-specific
human monoclonal antibodies from mice engineered with human Ig
heavy and light chain YACs. Nat Genet 1994;7:13–21. [CrossRef]
- 28. Mompó SM, González-Fernández Á. Human Monoclonal Antibodies,
Antigen-Specific Human Monoclonal Antibodies from Transgenic
Mice. Methods in Molecular Biology, Vol 1060. Totowa, NJ: Humana
Press; 2014. p.245–276. [CrossRef]
- 29. Calvo E, Rowinsky EK. Clinical experience with monoclonal antibodies
to epidermal growth factor receptor. Curr Oncol Rep 2005;7:96–103.
[CrossRef]
- 30. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, et al. Dual
mode of action of a human anti-epidermal growth factor receptor
monoclonal antibody for cancer therapy. J Immunol 2004:173:4699–
4707. [CrossRef]
- 31. Keler T, Halk E, Vitale L, et al. Activity and safety of CTLA-4 blockade
combined with vaccines in cynomolgus macaques. J Immunol
2003;171:6251–6259. [CrossRef]
- 32. Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully
human monoclonal antibody to RANKL, inhibits bone resorption
and increases BMD in knock-in mice that express chimeric (murine/
human) RANKL. J Bone Miner Res 2009;24:182–195. [CrossRef]
- 33. Zou X, Lan G, Osborn MJ, Brüggemann M. The Generation of Transgenic
Mice Expressing Human Antibody Repertoires. In: Kontermann R,
Dübel S, editors. Antibody Engineering. Berlin, Heidelberg: Springer
Protocols Handbooks; 2010. p.235–254. [CrossRef]
- 34. Brüggemann M, Osborn MJ, Ma B, et al. Human antibody production
in transgenic animals. Arch Immunol Ther Exp (Warsz) 2015;63:101–
108. [CrossRef]
- 35. Oshimura M, Uno N, Kazuki Y, Katoh M, Inoue T. A pathway from
chromosome transfer to engineering resulting in human and mouse
artificial chromosomes for a variety of applications to bio-medical
challenges. Chromosome Res 2015;23:111–133. [CrossRef]
- 36. Tomizuka K, Yoshida H, Uejima H, et al. Functional expression
and germline transmission of a human chromosome fragment in
chimaeric mice. Nat Genet 1997;16:133–143. [CrossRef]
- 37. Duvall M, Bradley N, Fiorini RN. A novel platform to produce human
monoclonal antibodies: The next generation of therapeutic human
monoclonal antibodies discovery. mAbs 2011;3:203–208. [CrossRef]
- 38. Frenzel A, Schirrmann T, Hust M. Phage display-derived human
antibodies in clinical development and therapy. mAbs 2016;8:1177–
1194. [CrossRef]
- 39. Nelson AL, Dhimolea E, Reichert JM. Development trends for
human monoclonal antibody therapeutics. Nat Rev Drug Discovery
2010;9:767–774. [CrossRef]
- 40. Rajput R, Khanna M, Pradhan HK. Phage-Display Technology for the
Production of Recombinant Monoclonal Antibodies. Mater Meth
2014;4:873. [CrossRef]
J Basic Clin Health Sci 2020; 4:197-204 Sanlav G et al. A review
204
- 41. Rodi D, Makowski L. Phage-display technology –finding a needle
in a vast molecular haystack. Curr Opin Biotechnol 1999;10:87–93.
[CrossRef]
- 42. Willats WGT. Phage display: practicalities and prospects. Plant Mol
Biol 2002;50:837–854. [CrossRef]
- 43. Rami A, Behdani M, Yardehnavi N, Habibi-Anbouhi M, Kazemi-
Lomedasht F. An overview of the application of phage display
technique in immunological studies. Asian Pacific J Tropic Biomed
2017;7:599–602. [CrossRef]
- 44. Dübel S, Stoevesandt O, Taussig MJ, Hust M. Generating recombinant
antibodies to the complete human proteome. Trends Biotechnol
2010;28:333–339. [CrossRef]
- 45. Schwimmer LJ, Huang B, Giang H, et al. Discovery of diverse and
functional antibodies from large human repertoire antibody libraries.
J Immunol Methods 2013;391:60–71. [CrossRef]
- 46. Lu R, Hwang Y, Liu I, et al. Development of therapeutic antibodies for
the treatment of diseases. J Biomed Sci 2020;27:1. [CrossRef]
- 47. Hoet RM, Cohen EH, Kent RB, et al. Generation of high-affinity
human antibodies by combining donor-derived and synthetic
complementarity-determining-region diversity. Nat Biotechnol
2005;23:344–348. [CrossRef]
- 48. Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD.
Isolating and engineering human antibodies using yeast surface
display. Nat Protoc 2006;1:755–768. [CrossRef]